USEFULNESS OF CV 205-502 IN A CASE OF ALLERGY TO ERGOT-DERIVED DRUGS

This study reports a case of allergy to ergot-derived drugs in a patie nt with a prolactin (PRL)-secreting microadenoma. The anamnesis reveal ed allergic reactions to the administration of analgesics and antibiot ics. The administration of dopamine agonist drugs, such as bromocripti ne (BRC; 2.5 mg) or lisuride (0.2 mg), induced after a few minutes the appearance of nausea, vomiting, postural hypotension, headache, edema of the glottis with dispnea and acroedema. The edemas disappeared a f ew hours after the administration of antihistaminic drugs while nausea , vomiting, postural hypotension and headache persisted for a few days . Therefore, the patient was tested with another dopamine agonist none rgot-derived drug, quinagolide (CV 205-502), which did not cause side effects or allergic reactions. Furthermore, not only was the responsiv eness to the drug optimal but it also normalized the PRL levels, and m enses reappeared after more than a 5-year amenorrhea. This report sugg ests that ergot-derived drugs, such as lisuride and BRC, seldom induce allergic reactions apart from common side effects. Consequently, the feasibility of using a new drug with a different molecular structure ( non-ergot derived) effective in the therapy of hyperprolactinemic synd romes represents a good alternative to conventional therapy.